Department of Pharmaceutics, Centre for Pharmaceutical Sciences, University College of Engineering, Science and Technology (UCESTH), Jawaharlal Nehru Technological University, Hyderabad, Telangana-50085, India.
Nanoemulsions have attracted a lot of attention as innovative drug delivery techniques because they can increase the solubility, stability, and bioavailability of drugs that are not water-soluble. In a variety of biological applications, such as cancer, ophthalmology, and vaccine administration, their small droplet size, generally between 20 and 200 nm, permits improved permeability, controlled release, and targeted delivery. Nanoemulsions have significant technological and regulatory obstacles in spite of their promise for medicinal use. The lack of standardized definitions, restricted characterization procedures, scalability problems, and particular pharmacopeial requirements are a few of these. The regulatory environment around nanoemulsions is thoroughly examined in this paper, with particular attention paid to significant international organizations including the FDA, EMA, PMDA, CDSCO, MHRA, and NMPA. It talks about quality control issues, clinical trial regulations, and categorization difficulties. Recent developments in regulatory science, such as the use of AI/ML technologies and public-private partnerships, indicate encouraging future prospects, while case studies of authorized nanoemulsion-based products demonstrate the viability of clinical translation. The analysis also highlights the pressing need for standard testing procedures, worldwide regulatory harmonization, and the use of green nanotechnology to support sustainable manufacturing practices. By filling up these gaps, nanoemulsions can be successfully incorporated into the biomedical and pharmaceutical pipelines, opening the door to safer, more effective, and patient-centered treatments.
Nanoemulsions have become a viable medication delivery mechanism. Nanoemulsions, which are distinguished by their nanometer-sized droplets, have special qualities including increased stability, higher bioavailability, and a high solubilization capacity, which make them perfect for administering medications that are poorly soluble [1]. Because these systems can increase the solubility and bioavailability of poorly water-soluble medications, provide controlled drug release, and enhance the therapeutic efficacy of active pharmaceutical ingredients (APIs), they have attracted a lot of interest from the biomedical and pharmaceutical industries [2]. Because of their adaptability, nanoemulsions may be given in a number of methods, including oral, intravenous, transdermal, ophthalmic, and mucosal delivery, which increases their use in contemporary therapies [3]. The transition of nanoemulsion-based products from lab research to clinical use is fraught with regulatory challenges, despite their apparent benefits. The safety evaluation and quality control of nanoemulsions are complicated by their complex physicochemical properties, which differ from those of typical pharmaceutical formulations. These features include a large surface area, dynamic interfacial behavior, and the possibility of unanticipated biological interactions [4]. As of yet, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) lack standardized and nano-specific regulatory frameworks that adequately address the unique properties of nanoemulsions [5].The absence of established characterisation techniques, a dearth of toxicological information unique to nanomaterials, and ambiguous standards for proving bioequivalence and long-term safety are some of the main obstacles [6].Furthermore, uniform regulatory monitoring across countries is further hampered by the lack of widely recognized terminology and categorization schemes for nanoemulsions [7]. The development of goods based on nanoemulsions is thus delayed as inventors and manufacturers struggle to match formulation techniques with regulatory requirements. The goal of this paper is to present a thorough examination of the regulatory environment that currently governs nanoemulsions in medication delivery and biological applications. To enable the safe and effective application of nanoemulsions in medical treatment, it will critically assess the current recommendations, point out current issues, and suggest methods for improving regulatory uniformity and clarity [8].
2. Nanoemulsions
Oil, water, and surfactants combine to form nanoemulsions, which are emulsions at the nanoscale with droplet sizes usually between 20 and 200 nanometers [9]. Two immiscible liquids, often water and oil, stabilized by surfactants and/or co-surfactants, form nanoemulsions, which are kinetically stable colloidal dispersions [10]. Nanoemulsions are significantly more stable than conventional emulsions resisting sedimentation, flocculation, and creaming due to their large interfacial surface area and tiny droplet size. Poorly water-soluble medications become more soluble, absorbable, and bioavailable because of their specific nanostructure, which makes them particularly useful in pharmaceutical and biological applications [11]. Numerous drug delivery methods, including transdermal, ocular, nasal, intravenous, and oral, have been studied using nanoemulsions. By enhancing membrane penetration and shielding bioactive from enzymatic breakdown, they make it easier to distribute lipophilic medications, vaccines, peptides, and genes [12,13]. Additionally, antibiotic therapies, cancer therapy, and diagnostic imaging are utilizing their ability for controlled release and targeted delivery [14].
2.1 Composition and types of nanoemulsions
The elements, varieties, and techniques of preparation of nanoemulsions are described in depth in this section. The overall composition of the nanoemulsion is shown in Figure 1. Four essential ingredients are usually used in the formulation of a nanoemulsion: the oil phase, the aqueous phase, surfactants, and co-surfactants.
2.1.1 Surfactants: By reducing the tension that exists amongst the water and oil phases, surfactants—amphiphilic molecules—stabilize the nanoemulsion. In nanoemulsion formulations, ionic surfactants such as sodium dodecyl sulphate (SDS) and non-ionic surfactants such as polysorbates (like Tween 80) and sorbitan esters (like Span 80) are commonly used. The choice of surfactant affects the nanoemulsion's stability, toxicity, and size of droplets [15].
2.1.2 Oil Phase: The oil phase is extremely helpful for lipophilic drugs, which are often poorly soluble in water. Commonly used oils include long-chain triglycerides (like soybean oil), medium- chain triglycerides (like caprylic/capric triglycerides), and non-ionic surfactant oils (like isopropyl myristate). The choice of oil is influenced by the application technique, the targeted release profile, & the medication's solubility. Along with contributing to influencing the droplet size and stability of the nanoemulsion, the oil phase affects the drug loading capacity and release kinetics.
2.1.3. Co-surfactants: Co-surfactants, such alcohols (like ethanol and propylene glycol) or glycols (like polyethylene glycol), are frequently added to improve the interfacial film's flexibility and further lower interfacial tension. This stabilizes nanoemulsion and permits the production of smaller droplets. Additionally, co-surfactants have the ability to alter the formulation's viscosity, which is essential for topical and transdermal applications [16].
2.1.4 Aqueous Phase: The aqueous phase, which is typically composed of purified water, is the continuous phase in oil-in-water (O/W) nanoemulsions or the dispersed phase in water-in-oil (W/O) nanoemulsions. For parenteral and ophthalmic use, some formulations may include buffers or electrolytes in the aqueous phase to maintain osmolarity and pH stability. The composition of the aqueous phase can have a significant effect on droplet formation and nanoemulsion stability [17].
2.2 Types of nanoemulsions
Nanoemulsions may be categorized into three main groups according to the features of the continuous and dispersed phases.
2.2.1 O/W (oil in water) Nanoemulsions
The oil phase of O/W nanoemulsions is dispersed as microscopic droplets inside the continuous aqueous phase. These formulations are particularly useful for the topical, parenteral, and oral administration of lipophilic drugs. For drugs that are poorly soluble in water, O/W nanoemulsions can enhance absorption, provide a controlled release profile, and boost solubility and bioavailability. They are widely used in the food, cosmetic, and pharmaceutical industries due to their stability and ease of formation.
2.2.2 W/O (water in oil) Nanoemulsions
W/O nanoemulsions are composed of water droplets dispersed throughout an oil phase. Although less prevalent, they are useful for topical or transdermal delivery of hydrophilic medicines because the oil phase can function as a barrier to regulate drug release. Because W/O nanoemulsions break the stratum corneum and have a reservoir effect, they are extremely helpful in increasing the penetration of active substances through the skin. They are often less stable than O/W nanoemulsions, though, and stability may need to be maintained by carefully choosing the surfactants [18].
2.2.3 Bicontinuous Nanoemulsions
Both the water and oil phases are distributed over a continuous network in bicontinuous nanoemulsions; there are no noticeable droplets. These intricate structures can be utilized to deliver both hydrophilic and lipophilic medications at the same time since combination of surfactants and co-surfactants stabilizes them. Because bicontinuous nanoemulsions may be designed to react to environmental cues like pH or temperature, they are especially intriguing for their potential in targeted delivery and controlled medication release.
Table 1. Advantage and disadvantage of nanoemulsions in drug Delivery [19]
|
S.No. |
Advantage |
Disadvantage |
|
1. |
Surface area and free energy, nanoemulsions are useful for material transportation. |
Production and formulation higher costs |
|
2. |
Improve their stability by not displaying innate problems such creaming, flocculation, coalescence, and sedimentation. |
Stability in nanoemulsion formulations can be complex. |
|
3. |
Created in a variety of forms, including liquids, foams, creams, and sprays, offering a wide range of application options. |
Heavily rely on surfactants. |
|
4. |
Non-toxic and non-irritant. |
Maintaining long-term stability may be challenging |
|
5. |
Contains biocompatible surfactants. |
Transition may impact the stability. |
|
6. |
Not cause damage to healthy living cells. |
There may be difficulties with increasing output from experimental to industrial levels. |
|
7. |
Tiny enough to go through the tough skin surface |
Surfactants may have limitations or undesirable effects. |
3. Applications in drug delivery and biomedical fields
3.1 Nanoemulsion in Drug Delivery
In a variety of drug delivery methods, nanoemulsions have become adaptable carriers with special benefits for solubilizing hydrophobic medications and enhancing bioavailability. Key uses of nanoemulsions in medication delivery include the following:
3.1.1 Topical Drug Delivery: Improved solubility of lipophilic medicines in the oil phase is provided by topical pharmaceutical nanoemulsions. Oil-in-water (O/W) nanoemulsions' dispersion phase offers an ideal setting for the dissolution of biopolymers like alginate, enabling formulation rheology and texture adjustments. The continuous, gentle phase makes it easier to apply medications through the skin barrier. According to studies, hydrophobic medications are administered more effectively by nanoemulsions than by suspensions in permeation tests.
3.1.2 Ocular Drug Delivery: A potential method for increasing the bioavailability of medications given to the eyes is the use of nanoemulsions for ocular drug administration. Nanoemulsions can be used to create ocular medication delivery systems because of its tiny droplet size and adjustable characteristics.
3.1.3 Intravenous Drug Delivery: In an effort to improve the bioavailability and therapeutic effectiveness of pharmaceutical medications, nanoemulsions have been studied for intravenous drug administration. This delivery method entails dissolving the medication in the dispersion phase of nanoemulsions, which are subsequently tested for delivery effectiveness under circumstances that closely resemble actual physiological settings.
3.1.4 Intranasal Drug Delivery: Intranasal drug delivery, which offers a non-invasive method of drug administration, has been implemented using nanoemulsions. This method enhances medication solubility and delivery effectiveness in the nasal cavity by using the special qualities of nanoemulsions [20].
3.1.5 Oral Drug Delivery: Pharmaceutical medications have been dissolved in the dispersion phase of nanoemulsions, which have been investigated for oral drug administration. The bioavailability of formulations is evaluated under circumstances that mimic those found in the walls of the small intestine. Enhancing medication absorption and improving therapeutic results are the goals of this application.
3.1.6 Ultrasound Imaging Agents: The adaptability of nanoemulsions in diagnostic applications has been demonstrated by their use as ultrasonic imaging agents. Perfluorocarbon-containing nanoemulsions, for instance, have been made for quantitative molecular imaging. Imaging-guided therapeutics can be made possible by engineering these formulations for multifunctionality [21].
3.1.7 Multifunctional Nanoemulsion Platforms: Multipurpose platforms for imaging-guided treatments can be provided by nanoemulsions. These platforms may include a variety of components, including therapeutic medicines for targeted therapies, fluorescent dyes for near-infrared fluorescence (NIRF) imaging, and iron oxide nanocrystals for magnetic resonance imaging. A thorough evaluation of the platform's usefulness in imaging and therapeutic applications is made possible by this method [22].
3.2 Nanoemulsion biomedical fields
The distinct physicochemical characteristics, which include their vast surface area, tiny droplet size, and capacity to encapsulate both lipophilic and hydrophilic bioactive substances, numerous applications for nanoemulsions have been demonstrated in the biomedical domain. These characteristics enable better bioavailability, controlled release, targeted distribution, and improved drug solubility—all of which are essential for contemporary treatments and diagnostics [23]
3.2.1 Systems for Drug Delivery
Nanoemulsions are widely employed as drug delivery vehicles, especially for medications that are not highly soluble in water. Their ability to improve drug solubility and absorption makes them suitable for oral, intravenous, transdermal, and ocular administration [24]. For instance, nanoemulsions have been used to improve the solubility and penetration of drugs like paclitaxel, cyclosporine, and curcumin, therefore enhancing their bioavailability [25].
3.2.2 Treatment for Cancer
By acting as efficient nanocarriers, nanoemulsions in cancer can carry chemotherapeutic drugs straight to tumor locations, reducing systemic toxicity and improving treatment efficiency. To identify and bind tumor-specific markers, targeted nanoemulsions can have their surfaces altered using ligands or antibodies [26]. Nanoemulsions containing medications like as docetaxel and doxorubicin have been demonstrated in several trials to have better tumor suppression and fewer adverse effects [27].
3.2.3 Delivery of Vaccines
In vaccine formulations, nanoemulsions have shown great promise as adjuvant systems. They can trigger both systemic and mucosal immune responses and aid in mucosal administration (for example, intranasal or oral methods). Oil-in-water nanoemulsions, for instance, have been utilized to increase the immunogenicity of hepatitis B and influenza vaccinations [28].
3.2.4. Applications of Antimicrobials and Antivirals
For better delivery and longer protection against bacterial, fungal, and viral infections, antimicrobial medications or essential oils can be encapsulated in nanoemulsions. Studies have demonstrated the effectiveness of nanoemulsion formulations in the treatment of skin infections and the inhibition of biofilm formation [29]. Additionally, it has been shown that nanoemulsions have inherent antibacterial activity due to their surfactant composition and nanoscale droplet size [30].
3.2.5 Delivery of Genes
Since they are easier to produce and have less immunogenicity than viral vectors, nanoemulsions are being researched as non-viral gene therapy vectors. Through endocytosis, they can promote cellular absorption and shield nucleic acids from enzymatic destruction [31].
3.2.6 Imaging for Diagnostics
Nanoemulsions can be used as contrast agents in biomedical imaging techniques such as magnetic resonance imaging (MRI), ultrasound, and optical imaging. Nanoemulsions enhance contrast and targeting specificity in sick tissues by adding imaging agents into the oil phase [32].
4. Regulatory guidelines for Nanoemulsions
The nanoscale, nanoemulsions - despite their potential for medication delivery and medicinal applications - face regulatory uncertainties. The demand for standardized frameworks that can effectively handle the characterisation, safety, effectiveness, and quality control of these intricate systems is reflected in the changing worldwide regulatory environment.
4.1 Overview of global regulatory bodies (FDA, EMA, PMDA, CDSCO, MHRA, NMPA)
Multiple international agencies govern the approval and regulation of pharmaceutical products, including those utilizing nanotechnology platforms such as nanoemulsions:
4.1.1 United States Food and Drug Administration (USFDA):
While the FDA does not provide nanoemulsion-specific guidelines, it has issued several documents that pertain to nanotechnology. The 2014 FDA guidance suggests a case-by-case approach to assess whether a product involves nanotechnology and requires additional safety considerations [33].
4.1.2 European Medicines Agency (EMA):
The EMA has issued a “Reflection Paper on Nanotechnology-Based Medicinal Products” (2022), which discusses general considerations for quality, safety, and efficacy, but lacks nanoemulsion-specific regulations [34].
4.1.3 Pharmaceuticals and Medical Devices Agency (PMDA, Japan):
PMDA follows ICH guidelines but does not have separate policies for nanoemulsions. However, nanomedicines are reviewed with added scrutiny regarding safety, toxicokinetic, and manufacturing quality [35].
4.1.4 Central Drugs Standard Control Organization (CDSCO, India):
CDSCO recognizes the importance of nanotechnology in pharmaceuticals and follows WHO and ICH guidelines. However, it lacks formal, nano-specific regulatory protocols and currently evaluates such formulations under conventional drug frameworks [36].
4.1.5 Medicines and Healthcare products Regulatory Agency (MHRA, UK):
MHRA aligns closely with EMA and evaluates nano-formulations on a case-by-case basis. There is currently no distinct regulatory pathway for nanoemulsions, although safety and characterization are emphasized [37].
4.1.6 National Medical Products Administration (NMPA, China):
The NMPA has recently issued guidelines addressing nanomaterials, focusing on physicochemical characterization, bioequivalence, and toxicology for nanoscale formulations [38].
4.2 Classification issues (are Nanoemulsions "nanoscale" by regulation?)
One major regulatory uncertainty in relation to nanoemulsions is that they are classified as "nanomaterials." Particle sizes between 1 and 100 nm are commonly used in regulatory definitions of goods based on nanotechnology (e.g., by the European Commission) [39]. Nonetheless, nanoemulsions are in a gray area of regulation as their droplet sizes frequently reach 200 nm or greater. Some organizations, like the FDA, use a more comprehensive approach that takes into account the characteristics and behaviors of nanoscale particles, while others only look at particle size. Therefore, unless their behavior, function, or risk profile demands it, nanoemulsions may not always be categorized as "nanoscale" materials and may avoid nano-specific inspection [40].
4.3 Requirements for clinical trials, safety, and manufacturing
The nanoscale components, the regulatory requirements for medicines based on nanoemulsions are more complex than those for conventional drug development procedures.
4.3.1 Preclinical and Clinical Assessment:
Thorough toxicological investigations are crucial, encompassing immunotoxicity, genotoxicity, and long-term biodistribution. Regulatory bodies need comprehensive explanations for the selection of particle size, surfactants, and excipients [41].
4.3.2 Physicochemical Characterization:
A thorough examination of the pH, viscosity, zeta potential, droplet size distribution, and interfacial tension is anticipated. To satisfy regulatory requirements, methods such differential scanning calorimetry (DSC), transmission electron microscopy (TEM), and dynamic light scattering (DLS) are employed [42].
4.3.3 GMP:
Manufacturing must adhere to GMP guidelines, paying special attention to scalability, sterility (for parenteral routes), and batch repeatability. For the stability and homogeneity of nanoemulsions, agencies could need particular validation [43].
4.3.4 Quality-by-Design (QbD) strategy:
Organizations such as the FDA and EMA promote a QbD strategy in nanoemulsion formulation, incorporating risk-based evaluation at every stage of the development process [44].
4.3.5 Labels and Risk Communication:
Although enforcement varies, several organizations (such as the EMA and NMPA) advise that product labels clearly describe nano-scale features and potential nano-specific dangers.
5. Regulatory challenges
Although nanoemulsions are becoming more and more popular as prospective drug delivery and biological application vehicles, their regulatory environment is still undeveloped and disjointed. A number of significant obstacles still stand in the way of their expedited approval and commercialization.
5.1 Lack of harmonized definitions
The lack of a unified, internationally recognized definition for "nanomaterials" and "nanoemulsions" is a major regulatory obstacle for nanoemulsions. Nanoscale materials are defined by various regulatory bodies using different criteria, usually based on particle size (1–100 nm according to the European Commission) [45]. However, nanoemulsions are in a murky area when it comes to categorization because they frequently have droplet sizes up to 200 nm. For instance, the FDA takes into account whether nanotechnology imparts unique physicochemical features that might affect safety or efficacy rather than defining a precise size range [46]. EMA and CDSCO, on the other hand, typically depend more on case-by-case analysis or size-based criteria. Because sponsors must adjust to varying interpretations between jurisdictions, this regulatory inconsistency makes product development more difficult [47].
5.1.2 Issues in characterization, reproducibility, and scalability
Droplet size distribution, surface charge, interfacial tension, and surfactant type and concentration all significantly affect how well nanoemulsions work, which is complex, multicomponent systems. There aren't many defined techniques for describing these qualities, though, and different labs approaches can provide conflicting results [48].
5.1.2.1 Important difficulties include:
5.1.2.1.1 Droplet Size Distribution: Depending on sample preparation and measurement circumstances, instruments such as dynamic light scattering (DLS) may yield different size values.
5.1.2.1.2 Polydispersity: One of the biggest challenges is maintaining a limited size distribution for batch repeatability.
5.1.2.1.3 Scalability: Because of variations in homogenization, shear forces, and temperature profiles, formulations that function well at the laboratory scale may have stability or quality problems when scaled up [49]. Furthermore, even adjustments to process variables can significantly impact the stability and performance of nanoemulsions, raising regulatory issues regarding batch-to-batch variability and product consistency [50].
5.1.3 Absence of specific monographs or pharmacopeial standards
The major pharmacopoeias (such as USP, EP, and JP) do not have any official monographs or specialized chapters that expressly address nanoemulsions. Standardization in formulation development, quality testing, and regulatory assessment is hampered by this lack. Regulators and manufacturers rely on internal or ad hoc approaches, which might differ in sensitivity, dependability, and relevance, in the absence of defined compendial procedures or criteria. Furthermore, there is a lack of uniformity in the definition and evaluation of essential quality characteristics (CQAs), such as viscosity, zeta potential, and long-term stability, which causes regulatory ambiguity and approval delays [51]. Harmonized pharmacopeial standards for nanoemulsions are currently absent, despite efforts by a number of international working groups and projects (for instance, ICH Q12 and the OECD Working Party on Manufactured Nanomaterials) to create frameworks for evaluating nanomedicine [52].
6. Recent Developments
Significant advancements have been made in the creation, authorization, and marketing of pharmaceutical medicines based on nanoemulsions throughout the last ten years. Innovations in formulation science, changing regulatory environments, and cooperative efforts between public and private players are the main forces behind these developments. Nanoemulsions are becoming more and more popular as flexible delivery methods in biomedicine and pharmaceuticals, despite regulatory challenges.
6.1 Case studies of approved nanoemulsion based products
Despite the lack of established regulatory procedures for nanoemulsions, several formulations based on nanoemulsions have effectively reached the market, proving the technology's viability and therapeutic value:
6.1.1 An injectable nanoemulsion formulation called Clevidipine (Cleviprex®) is used to quickly lower blood pressure during surgery. Cleviprex, an FDA-approved medication, solubilizes the weakly water-soluble active ingredient via a lipid-based nanoemulsion [53].
6. 1.2 the word "nanoemulsion," Propofol (Diprivan®), a common anesthetic, is created as a nanoemulsion of oil and water. It is a great example of the successful use of nanoemulsion ideas to medicinal products [54].
6.1.3 The topical ophthalmic emulsion Restasis® (Cyclosporine ophthalmic emulsion) is authorized for the treatment of dry eye condition. It improves cyclosporine distribution across ocular tissues by using nanoemulsion technology [55].
6.1.4 Under dietary supplement restrictions, a number of nutraceuticals nanoemulsions, such as curcumin and CBD-based products, have made their way into consumer markets worldwide, particularly in the U.S. and the EU, despite not being certified medications [56]. These examples show how nanoemulsions can be used to administer hydrophobic medications, lessen systemic adverse effects, and enhance therapeutic results.
6.2 Innovations in regulatory science
Regulatory science is developing to meet the unique requirements of nano-formulations in response to the growing use of nanotechnology in medicine:
6.2.1 FDA’s Nanotechnology Task Force and its Emerging Sciences Working Group (ESWG)
In order to promote multidisciplinary methods to risk assessment and safety evaluation, the FDA's Nanotechnology Task Force and its Emerging Sciences Working Group (ESWG) have been actively creating review procedures for nanomaterials [57].
6.2.2 EMA’s Reflection Paper (2022)
The adoption of Quality-by-Design (QbD) principles and early contact between developers and regulators are encouraged in the Agency's Reflection Paper (2022) on nanomedicines [58].
6.2.3 ICH Q12 guideline
Throughout a product's commercial life, the ICH Q12 guideline facilitates more flexible and scientifically informed regulatory choices by supporting lifecycle management of complex goods, including nanoemulsions [59]. While maintaining the efficacy and safety of treatments based on nanoemulsions, these advancements seek to expedite development.
6.3 Role of public-private partnerships and initiatives
Establishing strong regulatory standards and developing nanoemulsion technologies need cooperation between regulators, industry, and academia.
6.3.1 The Nanotechnology Characterization Laboratory (NCL) was created in the United States by the National Cancer Institute (NCI) in partnership with the FDA and NIST. For businesses that manufacture nanomedicines, including nanoemulsions, the NCL provides preclinical testing and standardization services [60].
6.3.2 EU Nanomedicine Roadmap Initiative (NANOMED2020) By promoting translational research and standardizing regulatory approaches to nanomedicines throughout EU member states, the EU Nanomedicine Roadmap Initiative (NANOMED2020) promotes innovation [61]. Through the Innovative Medicines Initiative (IMI), the European Commission and the European Federation of Pharmaceutical Industries and Associations work together to develop knowledge-sharing platforms for nanomedicine research and regulatory harmonization [62]. Data exchange, regulatory convergence, and the creation of best practices that lower translational hurdles for nanoemulsion technologies are all made easier by these partnerships.
7. Future Perspectives
A forward-looking approach is necessary to get over the present technological, regulatory, and environmental barriers as nanoemulsions gain attraction in medication delivery and biological applications. Advanced digital tools, ecologically sensitive production, and unified worldwide frameworks are key components of the future of nanoemulsion technology.
7.1 Need for global regulatory harmonization
The creation of a single international regulatory framework for nanomedicine, including nanoemulsions, is one of the most urgent need. At the moment, developers face complexity and increased expenses because of differences in definitions, characterisation criteria, and data requirements between authorities including the FDA, EMA, PMDA, CDSCO, and NMPA.
• Encourage dependable and efficient development routes
• Facilitate reciprocal acceptance of regulatory evaluations
• Promote quicker access to treatments based on nanoemulsions globally.
Though development is still gradual, international forums like the International Pharmaceutical Regulators Programme (IPRP) and ICH are striving for convergence [63].
7.2 Development of standard testing protocols
There is an urgent need for standardized procedures for evaluating nanoemulsions that address surface tension, rheology, zeta potential, droplet size dispersion, and long-term stability.
Pharmacopeias such as USP, Ph. Eur., and JP would guarantee the following by establishing monographs:
• Reproducibility across production facilities and labs
• Improved uniformity from batch to batch
• Clarity in regulations for release testing and quality assurance
Standardization of test methods for nanomaterials has been started by organizations such as the OECD and ISO, however nanoemulsions have not yet received enough attention [64].
7.3 Consideration of AI/ML in nanoformulation regulatory review
Nanoemulsion design and regulatory assessment might be revolutionized by machine learning (ML) and artificial intelligence (AI).
7.3.1 Predictive modeling: AI is able to simulate biological interactions, improve formulations, and forecast physicochemical attributes.
7.3.2 Regulatory Applications: To help risk assessment and decision-making, machine learning algorithms can examine large toxicological and clinical datasets [65]. The FDA and other regulators are investigating their function in preclinical and regulatory workflows and have started programs like the action plan for AI/ML-Based Software as a Medical Device (SaMD) [66]. However, mechanisms that guarantee data integrity, explainability, and openness must be created in order to completely include AI into regulatory science.
7.4 Sustainable production and green nanotechnology
Sustainable and environmentally friendly production techniques must be given priority as the demand for nanoemulsions increases. Environmental and safety issues are brought up by the traditional usage of organic solvents and high-energy procedures.
Future paths consist of:
7.4.1 Green Solvents: Using biodegradable, low-toxicity oils and surfactants is known as "green solvents."
7.4.2 Low-Energy Emulsification: Techniques including phase inversion temperature (PIT) and spontaneous emulsification.
7.4.3 Integration of the Circular Economy: Reusing and recycling excipients and waste reduction techniques. The development of nanomaterials and processes that are safe for the environment and human health from the outset is encouraged by green nanotechnology [67].
8. CONCLUSION
Because they may improve the solubility, stability, and bioavailability of medicinal drugs, nanoemulsions have become a potent platform in drug delivery and biomedical applications. Their distinct physicochemical characteristics provide important benefits for the distribution of hydrophobic medications, enabling tailored delivery, and enhancing therapeutic results in fields including vaccine delivery, ophthalmology, and cancer. However, despite their potential, the regulatory landscape for nanoemulsions remains fragmented and complex. Challenges such as inconsistent global definitions, lack of standardized testing protocols, and absence of dedicated pharmacopeial monographs impede streamlined development and approval. Moreover, issues related to scalability, characterization, and reproducibility highlight the need for technical standardization and harmonized regulatory oversight. Recent developments including the approval of nanoemulsion-based drugs, regulatory science innovations, and collaborative public-private initiatives illustrate growing momentum and recognition within the scientific and regulatory communities. In order to advance the area going forward, it will be crucial to include artificial intelligence and machine learning into formulation development and regulatory assessment, as well as to prioritize sustainable, green nanotechnology techniques. To fully unlock the promise of nanoemulsions, it is essential to foster international collaboration aimed at regulatory harmonization, invest in the development of universally accepted quality standards, and promote responsible innovation. By addressing these challenges, nanoemulsions can be effectively translated from research to real-world clinical impact, improving patient care across diverse therapeutic areas.
REFERENCES
M. Swathi Ramani*, M. Sunitha Reddy and K. Anie Vijetha, Nanoemulsions in Drug Delivery and Biomedical Applications: Regulatory Challenges, Guidelines, and Future Directions, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 8, 2614-2628 https://doi.org/10.5281/zenodo.16939085
10.5281/zenodo.16939085
